Economic impact of heart failure with preserved ejection fraction: insights from the ALDO ‐DHF trial

ConclusionsIn this relatively young, oligosymptomatic, and with regard to the protocol without major comorbidities patient cohort, the overall costs are lower than expected compared with the HFrEF population. Further investigation is needed to investigate the impact of, for example, comorbidities and their effect over a longer period of time. Simultaneously, this analysis suggests that prevention of comorbidities are necessary to reduce costs in the health care system.

Source: ESC Heart Failure - January 26, 2020 Category: Cardiology Authors: Djawid Hashemi, Ludwig Dettmann, Tobias D. Trippel, Volker Holzendorf, Johannes Petutschnigg, Rolf Wachter, Gerd Hasenfu ß, Burkert Pieske, Antonia Zapf, Frank Edelmann Tags: Original Research Article Source Type: research